Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Yhenneko J. Taylor, Melanie D. Spencer, Rohan Mahabaleshwarkar & Thomas Ludden. (2019) Racial/ethnic differences in healthcare use among patients with uncontrolled and controlled diabetes. Ethnicity & Health 24:3, pages 245-256.
Read now
Read now
Lawrence Blonde, Chakkarin Burudpakdee, Victoria Divino, Brahim Bookhart, Jennifer Cai, Michael Pfeifer & Craig I. Coleman. (2018) The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. Current Medical Research and Opinion 34:8, pages 1501-1511.
Read now
Read now
Abhiroop Chakravarty, Mohini Rastogi, Praveen Dhankhar & Kelly F. Bell. (2018) Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Journal of Medical Economics 21:5, pages 497-509.
Read now
Read now
R. Brett McQueen, Sepehr Farahbakhshian, Kelly F. Bell, Kavita V. Nair & Joseph J. Saseen. (2017) Economic burden of comorbid chronic kidney disease and diabetes. Journal of Medical Economics 20:6, pages 585-591.
Read now
Read now
Bradley H. Curtis, Sarah Curtis, Daniel R. Murphy, James C. Gahn, Sinem Perk, Harry J. Smolen, James Murray, Nana Numapau, Jeffrey S. Bonner, Rong Liu, Jennal Johnson & Leonard C. Glass. (2016) Evaluation of a patient self-directed mealtime insulin titration algorithm: a US payer perspective. Journal of Medical Economics 19:6, pages 549-556.
Read now
Read now
Erin K. Buysman, Wing Chow, Henry J. Henk & Marcia F.T. Rupnow. (2015) Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Current Medical Research and Opinion 31:1, pages 137-143.
Read now
Read now
Articles from other publishers (18)
Athena Philis-Tsimikas, Addie L. Fortmann, Job G. Godino, James Schultz, Scott C. Roesch, Todd P. Gilmer, Emilia Farcas, Haley Sandoval, Kimberly L. Savin, Taylor Clark, Mariya Chichmarenko, Jennifer A. Jones & Linda C. Gallo. (2022) Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes. Trials 23:1.
Crossref
Crossref
Abdul Hamid Zargar, Sanjay Kalra, Prasanna Kumar K M, Sreenivasa Murthy, Vijay Negalur, Rajesh Rajput, Ashu Rastogi, Banshi Saboo, Surendra Kumar Sharma, Rakesh Sahay, S.R. Aravind, Shehla Shaikh, Mangesh Tiwaskar, Shahu Ingole & Sanjay Kamble. (2022) Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:8, pages 102528.
Crossref
Crossref
Kristina S. Boye, Maureen J. Lage & Vivian T. Thieu. (2022) The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis. Diabetes Therapy 13:2, pages 367-377.
Crossref
Crossref
Hannah König, A Rommel, Jens Baumert, Christian Schmidt, Hans-Helmut König, Christian Brettschneider & Alexander Konnopka. (2021) Excess costs of type 2 diabetes and their sociodemographic and clinical determinants: a cross-sectional study using data from the German Health Interview and Examination Survey for Adults (DEGS1). BMJ Open 11:4, pages e043944.
Crossref
Crossref
Rebecca S. Gold, Jonathan T. Unkart, Robyn L. McClelland, Alain G. Bertoni & Matthew A. Allison. (2021) Health insurance status and type associated with varying levels of glycemic control in the US: The multi-ethnic study of atherosclerosis (MESA). Primary Care Diabetes 15:2, pages 378-384.
Crossref
Crossref
Rajesh R. Mehta, Alison M. Edwards, Swapnil Rajpathak, Ajay Sharma, Kenneth J. Snow & Kristy Iglay. (2020) Effects of conformance to type 2 diabetes guidelines on health care resource utilization, clinical outcomes, and cost: A retrospective claims analysis. Journal of Clinical & Translational Endocrinology 19, pages 100215.
Crossref
Crossref
María Álvarez Casaño, María del Mar Alonso Montejo, Isabel Leiva Gea, Jose Manuel Jiménez Hinojosa, María Ángeles Santos Mata, Francisco Macías, María del Mar Romero Pérez, Marta de Toro, Gabriela Martínez, Pilar Munguira, Gustavo Vivas & Juan Pedro López Siguero. (2019) Estudio de costes directos de la diabetes mellitus tipo 1 en pacientes entre 2 y 16 años en Andalucía. Endocrinología, Diabetes y Nutrición 66:8, pages 480-486.
Crossref
Crossref
María Álvarez Casaño, María del Mar Alonso Montejo, Isabel Leiva Gea, Jose Manuel Jiménez Hinojosa, María Ángeles Santos Mata, Francisco Macías, María del Mar Romero Pérez, Marta de Toro, Gabriela Martínez, Pilar Munguira, Gustavo Vivas & Juan Pedro López Siguero. (2019) Study of direct costs of type 1 diabetes mellitus in Andalusian patients aged 2–16 years. Endocrinología, Diabetes y Nutrición (English ed.) 66:8, pages 480-486.
Crossref
Crossref
Anthony CannonYehuda HandelsmanMichael HeileMichael Shannon. (2018) Burden of Illness in Type 2 Diabetes Mellitus. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S5-S13.
Crossref
Crossref
Robert Brett McQueen, Marc D. Breton, Joyce Craig, Hayden Holmes, Melanie D. Whittington, Markus A. Ott & Jonathan D. Campbell. (2018) Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England. Journal of Diabetes Science and Technology 12:5, pages 992-1001.
Crossref
Crossref
Eugene E. WrightJr.Jr. & James R. GavinIIIIII. (2017) Clinical Use of Professional Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 19:S2, pages S-12-S-15.
Crossref
Crossref
Julio López-Bastida, Juan Pedro López-Siguero, Juan Oliva-Moreno, Magaly Perez-Nieves, Renata Villoro, Tatiana Dilla, María Merino, Dingfeng Jiang, Isaac Aranda-Reneo, Jesús Reviriego & Luis Alberto Vázquez. (2017) Social economic costs of type 1 diabetes mellitus in pediatric patients in Spain: CHRYSTAL observational study. Diabetes Research and Clinical Practice 127, pages 59-69.
Crossref
Crossref
Almina Kalkan, Johan Bodegard, Johan Sundström, Bodil Svennblad, Carl Johan Östgren, Peter Nilsson Nilsson, Gunnar Johansson & Mattias Ekman. (2017) Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice. Primary Care Diabetes 11:2, pages 184-192.
Crossref
Crossref
R. Brett McQueen, Marc D. Breton, Markus Ott, Helena Koa, Bruce Beamer & Jonathan D. Campbell. (2015) Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada. Journal of Diabetes Science and Technology 10:2, pages 366-377.
Crossref
Crossref
Christin Bexelius, Johan Lundberg, Xuan Wang, Jenny Berg & Hans Hjelm. (2013) Annual Medical Costs of Swedish Patients with Type 2 Diabetes Before and After Insulin Initiation. Diabetes Therapy 4:2, pages 363-374.
Crossref
Crossref
Christopher G. Parkin. (2013) Penny Wise and Pound Foolish: Will Shortsighted Cost Reduction Measures Compromise Patient Access to Promising Self-Monitoring of Blood Glucose Technology >. Journal of Diabetes Science and Technology 7:4, pages 979-982.
Crossref
Crossref
Kerry A. McBrien, Braden J. Manns, Betty Chui, Scott W. Klarenbach, Doreen Rabi, Pietro Ravani, Brenda Hemmelgarn, Natasha Wiebe, Flora Au & Fiona Clement. (2013) Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function. Diabetes Care 36:5, pages 1172-1180.
Crossref
Crossref
Andrea Mosca, Annunziata Lapolla & Philippe Gillery. (2013) Glycemic control in the clinical management of diabetic patients. Clinical Chemistry and Laboratory Medicine (CCLM) 51:4, pages 753-766.
Crossref
Crossref